Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Mallinckrodt
McKesson
Baxter
Harvard Business School

Last Updated: August 15, 2022

ZOLPIMIST Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Zolpimist, and when can generic versions of Zolpimist launch?

Zolpimist is a drug marketed by Aytu and is included in one NDA. There is one patent protecting this drug.

This drug has eighty-eight patent family members in ten countries.

The generic ingredient in ZOLPIMIST is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zolpimist

A generic version of ZOLPIMIST was approved as zolpidem tartrate by ACME LABS on April 23rd, 2007.

  Try it Free

Summary for ZOLPIMIST
International Patents:88
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for ZOLPIMIST
What excipients (inactive ingredients) are in ZOLPIMIST?ZOLPIMIST excipients list
DailyMed Link:ZOLPIMIST at DailyMed
Drug patent expirations by year for ZOLPIMIST
Drug Prices for ZOLPIMIST

See drug prices for ZOLPIMIST

Pharmacology for ZOLPIMIST
Anatomical Therapeutic Chemical (ATC) Classes for ZOLPIMIST

US Patents and Regulatory Information for ZOLPIMIST

ZOLPIMIST is protected by one US patents.

Patents protecting ZOLPIMIST

Buccal, polar and non-polar spray containing zolpidem
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF TRANSIENT INSOMNIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aytu ZOLPIMIST zolpidem tartrate SPRAY, METERED;ORAL 022196-001 Dec 19, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Premature patent expiration for: ZOLPIMIST

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
See Plans and Pricing ZOLPIMIST See Plans and Pricing

International Patents for ZOLPIMIST

See the table below for patents covering ZOLPIMIST around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2452675 Pulvérisation buccale contenant sildénafil (Buccal spray containing sildenafil) See Plans and Pricing
New Zealand 539284 Buccal, polar and non-polar spray or capsule containing drugs for treating pain See Plans and Pricing
World Intellectual Property Organization (WIPO) 2004019905 See Plans and Pricing
European Patent Office 1534236 CAPSULE OU VAPORISATEUR BUCCAL, POLAIRE ET NON POLAIRE CONTENANT DES MEDICAMENTS POUR LE TRAITEMENT DE TROUBLES MUSCULAIRES ET SQUELETTIQUES (BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING MUSCULAR AND SKELETAL DISORDERS) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2004019909 See Plans and Pricing
Canada 2581996 PULVERISATION BUCCALE, POLAIRE ET NON POLAIRE CONTENANT DE L'ALPRAZOLAM (BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ALPRAZOLAM) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZOLPIMIST

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2236132 300714 Netherlands See Plans and Pricing PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
2236132 CA 2015 00004 Denmark See Plans and Pricing PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
2236132 92636 Luxembourg See Plans and Pricing PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132 C300714 Netherlands See Plans and Pricing PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132 122015000006 Germany See Plans and Pricing PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
McKinsey
Medtronic
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.